After opening our US offices in Los Angeles only a few weeks ago, we are continuing our preparations for rewellio’s commercial launch internationally. We are happy to announce that Rewellio is now registered with the Food and Drug Administration, better known as the FDA, responsible for protecting and promoting public health through the control and supervision of many product categories including but not limited to medical devices in the United States of America.

This is yet another big milestone reached in our global efforts of bringing our rehabilitation platform to more people around the world. With this FDA registration completed, we are one step closer to reaching approximately 800,000 people suffering from a stroke in the United States every year.

If you are a therapist, patient or researcher in the United States – or anywhere else – and interested in rewellio’s rehabilitation platform, please reach out to us.